Sector News

Boston Scientific elects Yoshiaki Fujimori to Board

July 13, 2016
Life sciences

Boston Scientific Corporation announced today the election of Yoshiaki Fujimori to its board of directors, effective immediately.

Yoshiaki Fujimori is an adviser to the LIXIL Group Corporation (“LIXIL”), for which he served as president and chief executive officer from 2011 to 2016. Prior to joining LIXIL, Mr. Fujimori spent 25 years with GE, including positions as senior vice president and chief executive officer (CEO) of a number of Asian and global business divisions, including Medical Systems, Plastics and Capital, and was a member of the Corporate Executive Council before serving as chairman, president and CEO of GE Japan for more than three years. Mr. Fujimori started his career at Japanese trading company Nissho Iwai Corporation (now Sojitz).

Mr. Fujimori serves as an external director of Tokyo Electric Power Company, a role he has held since June 2012. He is also an external director for Takeda Pharmaceutical Company Limited. He previously served as chairman of the Japan Construction Material & Housing Equipment Industries Federation. He received his bachelor’s degree in petroleum engineering from the University of Tokyo and his master’s degree from Carnegie Mellon Graduate School of Business, where he serves as a lifetime member of the Board of Trustees.

“Fujimori-san is an accomplished business leader and brings significant insights on how large companies plan, execute and compete globally to our Board,” said Mike Mahoney, chief executive officer and chairman of the board, Boston Scientific. “We are delighted to welcome him to the Board.”

Source: Boston Scientific

comments closed

Related News

March 24, 2024

Johnson Matthey to sell its Medical Devices business for $700 million

Life sciences

Johnson Matthey Plc (JM; London) announced that it has signed a definitive agreement to sell 100% of its Medical Device Components business (MDC) to Montagu Private Equity (Montagu) for cash consideration of US$700 million (£550 million) on a cash free debt free basis.

March 24, 2024

Lonza acquires biologics manufacturing plant in California from Roche

Life sciences

Lonza AG (Basel, Switzerland) announced it has signed an agreement to acquire the Genentech large-scale biologics manufacturing site in Vacaville, Calif. from Roche (Basel, Switzerland) for $1.2 billion. The acquisition will significantly increase Lonza’s large-scale biologics manufacturing capacity.

March 24, 2024

Roquette to acquire IFF Pharma Solutions to boost global excipient presence

Life sciences

Roquette plans to acquire International Flavors & Fragrances (IFF) Pharma Solutions for an enterprise value of up to €2.85 billion (US$3.09 billion). With the acquisition set to close in the first half of 2025, the plant-based ingredient and pharmaceutical excipients supplier aims to reinforce its position in the pharmaceutical industry.

How can we help you?

We're easy to reach